Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up
- PMID: 12488411
- DOI: 10.1200/JCO.2002.12.111
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up
Abstract
Purpose: To investigate whether chemotherapy with etoposide and cisplatin (EP) is superior to cyclophosphamide, epirubicin, and vincristine (CEV) in small-cell lung cancer (SCLC).
Patients and methods: A total of 436 eligible patients were randomized to chemotherapy with EP (n = 218) or CEV (n = 218). Patients were stratified according to extent of disease (limited disease [LD], n = 214; extensive disease [ED], n = 222). The EP group received five courses of etoposide 100 mg/m(2) intravenously (IV) and cisplatin 75 mg/m(2) IV on day 1, followed by oral etoposide 200 mg/m(2) daily on days 2 to 4. The CEV group received five courses of epirubicin 50 mg/m(2), cyclophosphamide 1,000 mg/m(2), and vincristine 2 mg, all IV on day 1. In addition, LD patients received thoracic radiotherapy concurrent with chemotherapy cycle 3, and those achieving complete remission during the treatment period received prophylactic cranial irradiation.
Results: The treatment groups were well balanced with regard to age, sex, and prognostic factors such as weight loss, and performance status. The 2- and 5-year survival rates in the EP arm (14% and 5%, P =.0004) were significantly higher compared with those in the CEV arm (6% and 2%). Among LD patients, median survival time was 14.5 months versus 9.7 months in the EP and CEV arms, respectively (P =.001). The 2- and 5-year survival rates of 25% and 10% in the EP arm compared with 8% and 3% in the CEV arm (P =.0001). For ED patients, there was no significant survival difference between the treatment arms. Quality-of-life assessments revealed no major differences between the randomized groups.
Conclusion: EP is superior to CEV in LD-SCLC patients. In ED-SCLC patients, the benefits of EP and CEV chemotherapy seem equivalent, with similar survival time and quality of life.
Comment in
-
"The guard dies, it does not surrender!" progress in the management of small-cell lung cancer?J Clin Oncol. 2002 Dec 15;20(24):4618-20. doi: 10.1200/JCO.2002.20.24.4618. J Clin Oncol. 2002. PMID: 12488404 No abstract available.
Similar articles
-
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).Lung Cancer. 2005 May;48(2):251-61. doi: 10.1016/j.lungcan.2004.10.016. Epub 2004 Dec 15. Lung Cancer. 2005. PMID: 15829326 Clinical Trial.
-
Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.Saudi Med J. 2003 Jun;24(6):628-31. Saudi Med J. 2003. PMID: 12847592 Clinical Trial.
-
Phase II study of cyclophosphamide, doxorubicin, and vincristine (CAV) and etoposide plus cisplatin (EP) alternating chemotherapy combined with radiotherapy in small cell lung cancer.Yonsei Med J. 1989;30(1):30-7. doi: 10.3349/ymj.1989.30.1.30. Yonsei Med J. 1989. PMID: 2545051
-
Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung.Eur J Cancer. 1996 Mar;32A(3):438-43. doi: 10.1016/0959-8049(95)00608-7. Eur J Cancer. 1996. PMID: 8814688 Review.
-
Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer.Semin Oncol. 1986 Sep;13(3 Suppl 3):40-4. Semin Oncol. 1986. PMID: 3020699 Review.
Cited by
-
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.Nat Rev Clin Oncol. 2024 Aug;21(8):610-627. doi: 10.1038/s41571-024-00914-x. Epub 2024 Jul 4. Nat Rev Clin Oncol. 2024. PMID: 38965396 Review.
-
Total hysterectomy versus radical hysterectomy in neuroendocrine cervical cancer: a SEER-database analysis.J Cancer Res Clin Oncol. 2024 May 6;150(5):236. doi: 10.1007/s00432-024-05773-8. J Cancer Res Clin Oncol. 2024. PMID: 38710946 Free PMC article.
-
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241249690. doi: 10.1177/15330338241249690. Technol Cancer Res Treat. 2024. PMID: 38706247 Free PMC article. Clinical Trial.
-
Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.Clin Transl Oncol. 2024 Jul;26(7):1664-1673. doi: 10.1007/s12094-024-03387-7. Epub 2024 Feb 8. Clin Transl Oncol. 2024. PMID: 38329610
-
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.Front Immunol. 2024 Jan 22;15:1353889. doi: 10.3389/fimmu.2024.1353889. eCollection 2024. Front Immunol. 2024. PMID: 38322260 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials